Medikit (7749) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended December 31, 2024, increased 2.9% year-over-year to ¥17,342 million, with operating profit down 1.9% to ¥3,629 million and net profit attributable to shareholders up 1.1% to ¥2,155 million.

• Domestic sales growth was driven by new and existing medical device products, while overseas sales were impacted by the end of a major distribution contract.

• The company revised its mid-term management plan to adapt to changing market conditions and ensure steady growth.

Financial highlights

• Gross profit for the period was ¥6,764 million, with a gross margin of 39.0%.

• Comprehensive income decreased 10.6% year-over-year to ¥2,067 million.

• EPS for the period was ¥145.97, up from ¥126.95 in the prior year.

Outlook and guidance

• Full-year revenue is forecast at ¥22,385 million, up 2.4% year-over-year, with operating profit expected to decline 11.0% to ¥4,162 million.

• Net profit for the year is projected at ¥2,745 million, down 10.6% year-over-year.

• No changes have been made to the previously announced full-year guidance.